Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hemab Therapeutics HoldingsCOAG +3.48%11 Quick Ratio is 18.03 as of Dec. 2025, which is 13% above its 10-year median of 15.99. GuruFocus rates COAG with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,411 Biotechnology companies, Hemab Therapeutics Holdings ranks better than 90.57% on this metric.
Hemab Therapeutics Holdings (NAS:COAG) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Hemab Therapeutics Holdings Quick Ratio Related Terms
Hemab Therapeutics Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings Quick Ratio Chart
Hemab Therapeutics Holdings Annual Data
Trend
Dec24
Dec25
Quick Ratio
13.95
18.03
Hemab Therapeutics Holdings Semi-Annual Data
Dec24
Dec25
Quick Ratio
13.95
18.03
COAG vs ZLAB, SLS, IOVA: Quick Ratio Comparison
For the Biotechnology subindustry, Hemab Therapeutics Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hemab Therapeutics Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hemab Therapeutics Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Hemab Therapeutics Holdings's Quick Ratio falls into.
Hemab Therapeutics Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hemab Therapeutics Holdings (COAG) has a Quick Ratio of 18.03 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Hemab Therapeutics Holdings and its competitors. This is 13% above median its historical median of 15.99. Over the past decade, Hemab Therapeutics Holdings' Quick Ratio has ranged from 13.95 to 18.03. According to the industry distribution chart, Hemab Therapeutics Holdings ranks #133 out of 1411 companies in the Biotechnology industry, placing it in the top 9.4%.
Is Hemab Therapeutics Holdings' Quick Ratio too high?
Hemab Therapeutics Holdings' current Quick Ratio of 18.03 is 13% above median its 10-year median of 15.99. Over the past 10 years, this metric has ranged from a low of 13.95 to a high of 18.03. The Biotechnology industry median Quick Ratio is 3.56. Hemab Therapeutics Holdings' value of 18.03 is 406.5% above this industry median. Based on the distribution chart, Hemab Therapeutics Holdings ranks #133 out of 1411 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hemab Therapeutics Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Hemab Therapeutics Holdings' Quick Ratio compare to ZLAB and SLS?
According to the Biotechnology industry distribution chart, Hemab Therapeutics Holdings ranks #133 out of 1411 companies for Quick Ratio. This places Hemab Therapeutics Holdings in the top 9% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.56. Hemab Therapeutics Holdings' value of 18.03 is 406.5% above this benchmark. Historically, Hemab Therapeutics Holdings' own Quick Ratio has ranged from 13.95 to 18.03 over the past decade. While the company's 10-year median is 15.99 vs. the industry median of 3.56, Hemab Therapeutics Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.56, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hemab Therapeutics Holdings's current Quick Ratio of 18.03 is 406.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Hemab Therapeutics Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hemab Therapeutics Holdings's current Quick Ratio is 18.03, which is 13% above median its own 10-year median of 15.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hemab Therapeutics Holdings stock overvalued right now?
Hemab Therapeutics Holdings (COAG) has a current Quick Ratio of 18.03. The current Quick Ratio is 18.03, which is 13% above median its 10-year median of 15.99 and 406.5% above the Biotechnology industry median of 3.56. Hemab Therapeutics Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Hemab Therapeutics Holdings (COAG), the current Quick Ratio is 18.03 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.
11GF Score
Get the complete analysis for COAG
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COAG has been successfully added to your 
